A Molecular Tumor Board Reached for a RAF and MEK Clamp in RAF1 S257L Colorectal Cancer Complicated by Gaucher Disease

Gaucher disease took the standard options off the table before treatment started

Type 1 Gaucher disease produces splenomegaly, anemia and thrombocytopenia through glucocerebroside accumulation, and this patient arrived with baseline counts low enough that the authors state plainly they precluded standard chemotherapy and enrollment on a clinical trial. He got the standard regimens anyway, in sequence, and each round of cytotoxic therapy bought progression and neutropenic sepsis. By the time the board convened he was ECOG 3, which is the performance status at which most protocols stop enrolling.

An accelerated approval in ovarian cancer, borrowed for the colon

Avutometinib and defactinib reach US patients as AVMAPKI FAKZYNJA CO-PACK, approved under NDA 219616 to Verastem on May 8, 2025 following a priority review. The label covers adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have had prior systemic therapy. Nothing on that label touches colorectal cancer, RAF1, or combination with cetuximab, so every element of the regimen described here was prescribed outside it. The mechanistic argument is legible from the abstract: a compound that locks RAF and MEK together should blunt the reactivation that follows MEK inhibition alone, and adding cetuximab attacks the same pathway one node upstream in a RAS wild-type tumor.

Resistance arrived from four directions at once

Serial liquid biopsy at progression did not show a single new gatekeeper mutation. It showed the original RAF1 S257L still present at high allele fraction and now amplified, alongside EGFR ectodomain mutations of the sort that defeat cetuximab binding, KRAS alterations, and a MAP2K1 alteration sitting downstream of the clamp itself. The authors call the pattern polyclonal convergent MAPK and EGFR reactivation, which in practical terms means four distinct subclones arrived at the same destination and no single next agent addresses all of them.

A CC BY paper the public cannot read

The Oncologist runs this piece in its Precision Medicine Clinic column under a CC BY license, but the full text is distributed only as a PDF that the publisher's bot protection would not release, and no PubMed Central deposit exists. Everything above is drawn from the structured abstract, the author affiliations and the journal's own metadata. That leaves real gaps: the abstract never names the sequencing platform that identified RAF1 S257L, the specimen it ran on, or the vendor of the ctDNA assay used at progression, and it does not reproduce whatever the authors say about how an off-label supply of a co-packaged oncology product was obtained and paid for. Those are the operational questions a board faces on a Monday, and they sit inside the PDF.

Why This Matters to the APO|APE Reader

The May 8, 2025 ovarian approval this regimen borrows from is an accelerated one, granted on tumor response rate and duration of response, with continued approval contingent on a confirmatory trial. So the label backing a RAF1-driven colorectal request rests on unconfirmed clinical benefit in a different organ, which is a harder conversation with a payer than an ordinary off-label ask. Five authors across four institutions signed a report on one man, and the reason it reached a journal at all is that 0.5% drivers never accumulate the case volume to reach a trial. Reports like this one are the entire evidence base for that fraction of the colorectal panel, and the assay that found the variant is not named in the only part of the paper the public can read.